DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC60465 · Updated 24 October 2026

Lipid R6
Literature records

Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.

Table 1

Record: Initial library screening | Component order and reported values: Ionizable lipid / DOPE / cholesterol / C14-PEG2000 = 35:16:46.5:2.5 | Weight ratio / N/P: Screening stage uses crude lipid yield estimates. N/P not reported. | Interpretation: Sum 100; do not conflate with optimized R6.

Table 1

Record: Pre-optimization H9/R6 comparison | Component order and reported values: Ionizable lipid / DOTAP / cholesterol / DMG-PEG2000 = 35:16:46.5:2.5 | Weight ratio / N/P: General manual formulation: ionizable lipid:mRNA = 10:1 by mass. N/P not reported. | Interpretation: Sum 100; Methods description.

Table 1

Record: R6 optimized — Methods text | Component order and reported values: R6 / DOTAP / cholesterol / DMG-PEG2000 = 60:15:42.7:1.6 | Weight ratio / N/P: An optimized weight ratio is not assigned unambiguously here. N/P not reported. | Interpretation: Sum 119.3 molar parts, not 100 mol%.

Table 1

Record: R6 top DoE run #2 — SI Table 4 | Component order and reported values: R6 / DOTAP / cholesterol / PEG = 60:15:17:0.5 | Weight ratio / N/P: Lipid:mRNA weight ratio 7.5:1; the table does not further define the lipid basis. N/P not reported. | Interpretation: Sum 92.5; RAW 264.7 response 6.680 on a Log2 scale.

Table 2

Component: Lipid R6 | MW: 551.99 | Reported molar values: 35 | Calculated normalized mol%: 35.0000 | Calculated mg at 10 µmol: 1.9320 | Calculated mass fraction: 35.29%

Table 2

Component: DOTAP chloride | MW: 698.555 | Reported molar values: 16 | Calculated normalized mol%: 16.0000 | Calculated mg at 10 µmol: 1.1177 | Calculated mass fraction: 20.42%

Table 2

Component: Cholesterol | MW: 386.65 | Reported molar values: 46.5 | Calculated normalized mol%: 46.5000 | Calculated mg at 10 µmol: 1.7979 | Calculated mass fraction: 32.84%

Table 2

Component: DMG-PEG2000 | MW: 2507 | Reported molar values: 2.5 | Calculated normalized mol%: 2.5000 | Calculated mg at 10 µmol: 0.6268 | Calculated mass fraction: 11.45%

Table 3

Component: Lipid R6 | MW: 551.99 | Reported molar values: 60 | Calculated normalized mol%: 50.2934 | Calculated mg at 10 µmol: 2.7761 | Calculated mass fraction: 51.65%

Table 3

Component: DOTAP chloride | MW: 698.555 | Reported molar values: 15 | Calculated normalized mol%: 12.5733 | Calculated mg at 10 µmol: 0.8783 | Calculated mass fraction: 16.34%

Table 3

Component: Cholesterol | MW: 386.65 | Reported molar values: 42.7 | Calculated normalized mol%: 35.7921 | Calculated mg at 10 µmol: 1.3839 | Calculated mass fraction: 25.75%

Table 3

Component: DMG-PEG2000 | MW: 2507 | Reported molar values: 1.6 | Calculated normalized mol%: 1.3412 | Calculated mg at 10 µmol: 0.3362 | Calculated mass fraction: 6.26%

Table 4

Component: Lipid R6 | MW: 551.99 | Reported molar values: 60 | Calculated normalized mol%: 64.8649 | Calculated mg at 10 µmol: 3.5805 | Calculated mass fraction: 64.40%

Table 4

Component: DOTAP chloride | MW: 698.555 | Reported molar values: 15 | Calculated normalized mol%: 16.2162 | Calculated mg at 10 µmol: 1.1328 | Calculated mass fraction: 20.38%

Table 4

Component: Cholesterol | MW: 386.65 | Reported molar values: 17 | Calculated normalized mol%: 18.3784 | Calculated mg at 10 µmol: 0.7106 | Calculated mass fraction: 12.78%

Table 4

Component: DMG-PEG2000 | MW: 2507 | Reported molar values: 0.5 | Calculated normalized mol%: 0.5405 | Calculated mg at 10 µmol: 0.1355 | Calculated mass fraction: 2.44%

Table 5

LNP: R6 | GFP-positive cells shown in Fig. 4g: 51.0% | Experiment: RAW 264.7; 500 ng GFP mRNA/well; 24-well plates; 48 h; 37 °C

Table 5

LNP: ALC-0315 | GFP-positive cells shown in Fig. 4g: 48.1% | Experiment: Same displayed flow-cytometry comparison

Table 5

LNP: MC3 | GFP-positive cells shown in Fig. 4g: 9.80% | Experiment: Same comparison

Table 5

LNP: H9 | GFP-positive cells shown in Fig. 4g: 6.76% | Experiment: Same comparison

Table 5

LNP: Untreated control | GFP-positive cells shown in Fig. 4g: 0.14% | Experiment: Same comparison

Table 6

Ionizable lipid: H9 | RAW 264.7 mTP, mean ± SD: 4.790 ± 0.254 | HeLa mTP, mean ± SD: 10.274 ± 0.436 | n: 6

Table 6

Ionizable lipid: MC3 | RAW 264.7 mTP, mean ± SD: 6.909 ± 0.824 | HeLa mTP, mean ± SD: 9.509 ± 0.249 | n: 6

Table 6

Ionizable lipid: R6 | RAW 264.7 mTP, mean ± SD: 8.309 ± 0.389 | HeLa mTP, mean ± SD: 7.917 ± 0.334 | n: 6

Table 7

Record: R6 pre-DoE | Luciferase activity, mean ± SD (RLU): 70,550.5 ± 19,519.2 | n: 6

Table 7

Record: R6 post-DoE | Luciferase activity, mean ± SD (RLU): 107,760.7 ± 31,998.0 | n: 6

Table 8

Run: 1 | Lipid:mRNA mass ratio: 7.5 | R6: 60 | DOTAP: 20 | PEG: 1.5 | Cholesterol: 11 | RAW 264.7 response (Log2): 6.518

Table 8

Run: 2 | Lipid:mRNA mass ratio: 7.5 | R6: 60 | DOTAP: 15 | PEG: 0.5 | Cholesterol: 17 | RAW 264.7 response (Log2): 6.680

Table 8

Run: 3 | Lipid:mRNA mass ratio: 15 | R6: 30 | DOTAP: 10 | PEG: 1.5 | Cholesterol: 43.5 | RAW 264.7 response (Log2): 4.327

Table 8

Run: 4 | Lipid:mRNA mass ratio: 7.5 | R6: 30 | DOTAP: 20 | PEG: 2.5 | Cholesterol: 40 | RAW 264.7 response (Log2): 4.414

Table 8

Run: 5 | Lipid:mRNA mass ratio: 7.5 | R6: 30 | DOTAP: 10 | PEG: 2.5 | Cholesterol: 50 | RAW 264.7 response (Log2): 2.705

Table 8

Run: 6 | Lipid:mRNA mass ratio: 7.5 | R6: 60 | DOTAP: 10 | PEG: 2.5 | Cholesterol: 20 | RAW 264.7 response (Log2): 2.825

Table 8

Run: 7 | Lipid:mRNA mass ratio: 15 | R6: 60 | DOTAP: 10 | PEG: 2.5 | Cholesterol: 12.5 | RAW 264.7 response (Log2): 3.102

Table 8

Run: 8 | Lipid:mRNA mass ratio: 15 | R6: 60 | DOTAP: 20 | PEG: 0.5 | Cholesterol: 4.5 | RAW 264.7 response (Log2): 5.172

Table 8

Run: 9 | Lipid:mRNA mass ratio: 15 | R6: 60 | DOTAP: 10 | PEG: 0.5 | Cholesterol: 14.5 | RAW 264.7 response (Log2): 5.574

Table 8

Run: 10 | Lipid:mRNA mass ratio: 11.25 | R6: 60 | DOTAP: 20 | PEG: 2.5 | Cholesterol: 6.25 | RAW 264.7 response (Log2): 5.115

Table 8

Run: 11 | Lipid:mRNA mass ratio: 15 | R6: 45 | DOTAP: 20 | PEG: 2.5 | Cholesterol: 17.5 | RAW 264.7 response (Log2): 4.621

Table 8

Run: 12 | Lipid:mRNA mass ratio: 7.5 | R6: 45 | DOTAP: 10 | PEG: 0.5 | Cholesterol: 37 | RAW 264.7 response (Log2): 6.123

Table 8

Run: 13 | Lipid:mRNA mass ratio: 15 | R6: 30 | DOTAP: 20 | PEG: 0.5 | Cholesterol: 34.5 | RAW 264.7 response (Log2): 5.604

Table 8

Run: 14 | Lipid:mRNA mass ratio: 11.25 | R6: 45 | DOTAP: 15 | PEG: 1.5 | Cholesterol: 27.25 | RAW 264.7 response (Log2): 3.333

Table 8

Run: 15 | Lipid:mRNA mass ratio: 15 | R6: 30 | DOTAP: 15 | PEG: 2.5 | Cholesterol: 37.5 | RAW 264.7 response (Log2): 3.628

Table 8

Run: 16 | Lipid:mRNA mass ratio: 7.5 | R6: 30 | DOTAP: 20 | PEG: 0.5 | Cholesterol: 42 | RAW 264.7 response (Log2): 6.443

Table 8

Run: 17 | Lipid:mRNA mass ratio: 11.25 | R6: 30 | DOTAP: 10 | PEG: 0.5 | Cholesterol: 48.25 | RAW 264.7 response (Log2): 5.150

Table 9

Experiment: Muscle luciferase expression | Reported observation: R6 was lower than H9; does not support a general muscle-delivery advantage. | Conditions: Intramuscular Fluc mRNA, 0.2 mg/kg; 6 h; two mice/group; SI S27b.

Table 9

Experiment: Cy5-labelled RNA distribution | Reported observation: Strong injection-site signal with lower liver and spleen signal; fluorescence is not functional transfection. | Conditions: C57BL/6J; intramuscular Cy5-mLuc RNA, 0.3 mg/kg; 6 h; n = 3; SI S28a.

Table 9

Experiment: OVA vaccination | Reported observation: R6 induced lower anti-OVA IgG than ALC-0315 in the reported prime–boost study. | Conditions: 10 µg mOVA per administration; day-28 antibody readout; SI S28b.

Table 9

Experiment: Tolerability | Reported observation: Limited cell-viability and day-28 liver-enzyme studies were reported; no clinical safety inference. | Conditions: SI S27a and S28c–d.

Open the complete guide for source context →